Novo Nordisk Faces Investor Concerns Amid Profit Outlook
WHO:
Bloomberg - Mike Doustdar, Chief Executive Officer of Novo Nordisk
CNBC - Maziar Mike Doustdar, CEO of Novo Nordisk
CNBC - Jared Holz, healthcare sector specialist at Mizuho Securities
WHAT:
Bloomberg - CEO Mike Doustdar stated that the profitability of Wegovy will continue to improve, saying, "If that was not the case, we would not be launching the product in more and more markets."
CNBC - Novo Nordisk raised its forecasts for the second time in 2026, citing higher expectations for its obesity and diabetes drug sales.
CNBC - Adjusted sales for 2026 are now expected to be down 6% to flat at constant exchange rates, an increase from the previous forecast of a decline between 4% and 12%.
CNBC - Adjusted operating profit is now expected to be in a range of down 6% to flat, up from the earlier forecast of a drop between 4% and 12%.
Bloomberg - The profitability of Wegovy, a weight-loss pill, is described as "decent" by CEO Mike Doustdar.
Bloomberg - Novo Nordisk's U.S.-traded shares dropped more than 5% after disappointing guidance was released.
CNBC - Novo Nordisk expects adjusted sales to be down 6% to flat at constant exchange rates for 2026.
CNBC - The company previously anticipated adjusted sales would fall between 4% and 12%.
CNBC - Adjusted operating profit is expected to be in a range of down 6% to flat.
CNBC - Second-quarter sales rose to 78.49 billion kroner ($12.09 billion), up 3% in constant currency.
CNBC - Adjusted operating profit rose 11% in constant currency to 33.39 billion kroner.
CNBC - The Wegovy weight-loss pill generated 3.22 billion kroner in sales for the second quarter, slightly below the expected 3.27 billion kroner.
CNBC - The Wegovy pill has topped 5 million prescriptions since its launch in January.
WHERE:
CNBC - Copenhagen, Denmark, where Novo Nordisk's annual general meeting took place.
WHY:
CNBC - The company cited current prescription trends for GLP-1 injections, "intensifying" competition, and reduced obesity medicine coverage in Medicaid as reasons for the expected sales decline in U.S. operations.
CNBC - Lower realized prices in the U.S. are partly due to the "most favored nation" drug pricing agreement struck with Trump.
HOW:
CNBC - The rollouts of the Wegovy pill and a higher-dose version of the Wegovy injection have helped Novo Nordisk regain its footing in the GLP-1 market.
Bloomberg - CEO Mike Doustdar stated that the company is not discussing further discounts on its products at this time.
(UPDATED August 5, 2026 16:10 UTC)
Novo Nordisk has raised its forecasts for 2026 for the second time, driven by increased expectations for sales of its obesity and diabetes drug, Wegovy. CEO Mike Doustdar emphasized that the company's profitability will continue to improve, noting that they would not be expanding the product into more markets if that weren't the case. The adjusted sales and operating profit forecasts now expect a decline of 6% to flat, an improvement from earlier predictions of a drop between 4% and 12%.
--
(UPDATED August 5, 2026 13:38 UTC)
Novo Nordisk's CEO Mike Doustdar described the profitability of their weight-loss pill, Wegovy, as "decent," but the company's U.S.-traded shares dropped over 5% following disappointing sales guidance. The company now expects adjusted sales for 2026 to be down 6% to flat, a revision from their previous forecast of a decline between 4% and 12%, while second-quarter sales rose to 78.49 billion kroner, slightly below expectations for Wegovy sales. Doustdar also noted that they are not currently discussing further discounts on their products, citing factors like intensified competition and changes in Medicaid coverage as reasons for the anticipated sales decline.